Brussels, Belgium, 1st September 2022: EHDEN is delighted to announce that Lundbeck has become a Partner of the EHDEN Consortium. They now join the 11 Public Partners, and 12 Industry Partners, adding their expertise, resources, and support in creating an ecosystem for working with real world data across Europe. The private-public partnership is building a large-scale, federated network of data sources standardised to a common data model, which is enabling better health decisions, outcomes, and care for patients.
To date, EHDEN’s Data Partner network includes 166 data sources from 27 countries with >630 anonymous million records that are being mapped to the OMOP common data model. These Data Partners are supported by 47 certified small-to-medium-sized enterprises from 19 countries who assist the Data Partners with their data mapping. The project is already generating real world evidence that has been published in more than 60 publications, and has helped improve treatment in multiple diseases, including in COVID-19.
EHDEN is also committed to promoting and expanding an open science community, and to this end, runs the open and free training resource – the EHDEN Academy that has had more than 2,500 enrolees from 60 countries globally.
Lundbeck will work with project partners on health data science, evidence generation, developing EHDEN’s sustainability, and supporting neuroscience in Europe and the world via a 5-year EHDEN-driven neuroscience research programme.
Ingrid Sofie Harbo, Vice President, Head of Biometric Sciences, Lundbeck, said, “Joining the EHDEN Consortium provides us the opportunity to be part of an already-delivering effort regarding the standardisation of health data and health data advanced analytics. We see great opportunities in federated health data networks and are particularly excited about the 5-year neuroscience research programme currently in planning.”
Johan Luthman, Executive Vice President, Research & Development, Lundbeck, said, “Joining the EHDEN Consortium is a great opportunity for us to support the development and the sustainability of Europe’s federated health data network, an important asset in translating forefront science into transformative treatment outcomes. The open science and collaborative research promoted by EHDEN aligns well with our practices to reach our goal of being premier in neuroscience.”
Nigel Hughes, EHDEN EFPIA Project Lead and Scientific Director, Epidemiology, Janssen R&D, said, “Lundbeck’s decision to join us on our journey is another excellent endorsement of the EHDEN project. Their expertise in CNS disorders, neuroscience, and psychiatry strengthens the Consortium and network collaboration. We very much look forward to their contribution in evidence generation, health data science, EHDEN’s sustainability, and their valuable role in the 5-year neuroscience research programme.”
Every day, patients are not receiving optimal healthcare because we are not able to tap into the unlimited potential of real-world data. In response to this, EHDEN (European Health Data & Evidence Network) was created as a public-private partnership under the framework of the IMI2 (Innovative Medicines Initiative). EHDEN aspires to be the trusted observational research ecosystem to enable better health decisions, outcomes, and care, with a mission to provide a new paradigm for the discovery and analysis of health data in Europe, by building a large-scale, federated network of data sources standardised to a common data model.
The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialised in brain diseases. For more than 70 years, Lundbeck has been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.
Too many people worldwide live with brain diseases - complex conditions often invisible to others that nonetheless take a tremendous toll on individuals, families, and societies. Lundbeck is committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Every day, Lundbeck employees strive for improved treatment and a better life for people living with brain disease.
Lundbeck has approximately 5,600 employees in more than 50 countries, and products are available in more than 100 countries. Research programmes tackle some of the most complex challenges in neuroscience, and the pipeline is focused on bringing forward transformative treatments for which there are few, if any therapeutic options. Lundbeck has research facilities in Denmark and the United States, and production facilities are located in Denmark, France, and Italy.